Psoriasis is a chronic inflammatory skin disease that primarily affects the skin and joints. Although the disease is non-life threatening, psoriasis patients usually need lifelong care, which equals lifetime expenses. Many cost analysis studies on psoriasis have not been comprehensive in calculating both its direct and indirect costs, and there are very limited studies on the economic burden of this disease in Asian countries. Therefore, a systematic literature review was done to gain a comprehensive understanding of the economic burden of psoriasis throughout the world. Observational studies and Randomized Controlled Trials (RCTs) published in the period 2000 to 2014 and Reporting on the direct and indirect costs of psoriasis were included. The search for literatures in the PUBMED database using keyword “economic burden of psoriasis”, “direct cost” and “indirect cost” has produced 182 articles. Of all the articles identified, 37 reports studies have met the inclusion criteria. Direct costs were higher than indirect costs, with hospitalization, medication prescription, travel, and treatment costs as significant aspects. Loss of productivity and wage (indirect costs borne by the patient) is not uncommon among psoriasis patients, accounting for 30-50% of the total cost, with an average of 2.2 work hours lost due to psoriasis. The limited information on such cost analysis justifies the need for future studies that address the cost of psoriasis therapies to provide the necessary transparency to guarantee reasonable medical care that considers the cost-benefit ratio and the best outcome for the patient’s quality of life.

1. Ahn, C. S., Gustafson, C. J., Sandoval, L. F., Davis, S. A., & Feldman, S. R. (2013). Cost effectiveness of biologic therapies for plaque psoriasis. American Journal of Clinical Dermatology, 14(4), 315-326. https://dx.doi.org/10.1007/s40257-013-0030-zPMid:23696234
2. Balogh, O., Brodszky, V., Gulácsi, L., Herédi, E., Herszényi, K., Jókai, H., & Holló, P. (2014). Cost-of-illness in patients with moderate to severe psoriasis: A cross-sectional survey in Hungarian dermatological centres. The European Journal of Health Economics, 15(1), 101-109. https://dx.doi.org/10.1007/s10198-014-0599-z PMid:24832841
3. Berger, K., Ehlken, B., Kugland, B., & Augustin, M. (2005). Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. Journal der Deutschen Dermatologischen Gesellschaft, 3(7), 511-518. https://dx.doi.org/10.1111/j.1610-0387.2005.05729.xPMid:15967010
4. Beyer, V., & Wolverton, S. E. (2010). Recent trends in systemic psoriasis treatment costs. Archives of Dermatology, 146(1), 46-54. https://dx.doi.org/10.1001/archdermatol.2009.319PMid:20083692
5. Carrascosa, J. M., Pujol, R., Dauden, E., Hernanz-Hermosa, J. M., Bordas, X., Smandia, J. A., & Ferrandiz, C. (2006). A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II). Journal of the European Academy of Dermatology and Venereology, 20(7), 840-845. https://dx.doi.org/10.1111/j.1468-3083.2006.01659.x
6. Chen, K. C., Hung, S. T., Yang, C. W. W., Tsai, T. F., & Tang, C. H. (2014). The economic burden of psoriatic diseases in Taiwan. Journal of Dermatological Science, 75(3), 183-189.https://dx.doi.org/10.1016/j.jdermsci.2014.05.012PMid:24953536
7. Christophers, E. (2001). Psoriasis–epidemiology and clinical spectrum. Clinical and Experimental Dermatology, 26(4), 314-320. https://dx.doi.org/10.1046/j.1365-2230.2001.00832.xPMid:11422182
8. Colombo, G. L., Di Matteo, S., Bruno, G., Girolomoni, G., & Vena, G. A. (2012). Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: A cost-effectiveness analysis of the ointment versus gel formulation. ClinicoEconomics and Outcomes Research, 4(1), 261-268. https://dx.doi.org/10.2147/CEOR.S35046PMid:23028233      PMCid:PMC3446829
9. Feldman, S. R., Burudpakdee, C., Gala, S., Nanavaty, M., & Mallya, U. G. (2014). The economic burden of psoriasis: A systematic literature review. Expert Review of Pharmacoeconomics & Outcomes Research, 14(5), 685-705. https://dx.doi.org/10.1586/14737167.2014.933671PMid:25052261
10. Finzi, A. F., Mantovani, L. G., & Belisari, A. (2001). The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. Associazione Italiana Studi Psoriasi. Journal of the European Academy of Dermatology and Venereology, 15(4), 320-324. https://dx.doi.org/10.1046/j.0926-9959.2001.00256.xhttps://dx.doi.org/10.1046/j.1468-3083.2001.00256.xPMid:11730042
11. Fowler, J. F., Duh, M. S., Rovba, L., Buteau, S., Pinheiro, L., Lobo, F., & Kosicki, G. (2008). The impact of psoriasis on health care costs and patient work loss. Journal of the American Academy of Dermatology, 59(5), 772-780. https://dx.doi.org/10.1016/j.jaad.2008.06.043PMid:19119095
12. Ghatnekar, O., Ljungberg, A., Wirestrand, L. E., & Svensson, Å. (2012). Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden–a cross-sectional study. European Journal of Dermatology, 22(2), 238-245.   PMid:22361745
13. Hankin, C., Feldman, S., Szczotka, A., Stinger, R., Fish, L., & Hankin D. (2005). A cost comparison of treatments of moderate to severe psoriasis. Drug Benefit Trends, 17(5), 200-214
14. Horn, E. J., Fox, K. M., Patel, V., Chiou, C. F., Dann, F., & Lebwohl, M. (2007). Are patients with psoriasis undertreated? Results of national psoriasis foundation survey. Journal of the American Academy of Dermatology, 57(6), 957-62. https://dx.doi.org/10.1016/j.jaad.2007.06.042PMid:17706322
15. Javitz, H. S., Ward, M. M., Farber, E., Nail, L., & Vallow, S. G. (2002). The direct cost of care for psoriasis and psoriatic arthritis in the United States. Journal of the American Academy of Dermatology, 46(6), 850-860. https://dx.doi.org/10.1067/mjd.2002.119669PMid:12063481
16. Larsen, C. G., Andersen, P. H., Lorentzen, H., Zachariae, C., Huldt-Nystrøm, T., Dotterud, L. K., & Qvitzau, S. (2013). Clinical and economic impact of etanercept in real-life: A prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER). European Journal of Dermatology, 23(6), 774-781.   PMid:24334009
17. Levy, A. R., Davie, A. M., Brazier, N. C., Jivraj, F., Albrecht, L. E., Gratton, D., & Lynde, C. W. (2012). Economic burden of moderate to severe plaque psoriasis in Canada. International Journal of Dermatology, 51(12), 1432-1440. https://dx.doi.org/10.1111/j.1365-4632.2011.05359.xPMid:23171010
18. Medical Development Division. (2013). Management of psoriasis vulgaris. Putrajaya, MY: Malaysia Health Technology Assessment Section.
19. Meyer, N., Paul, C., Feneron, D., Bardoulat, I., Thiriet, C., Camara, C., & Ortonne, J. P. (2010). Psoriasis: an epidemiological evaluation of disease burden in 590 patients. Journal of the European Academy of Dermatology and Venereology, 24(9), 1075-1082. https://dx.doi.org/10.1111/j.1468-3083.2010.03600.x
20. Mu, J. (2006). Correction. Journal of Epidemiology & Community Health, 60(9), 823-823. https://dx.doi.org/10.1136/jech.2005/040253corr2PMCid:PMC2566039
21. Mustonen, A., Mattila, K., Leino, M., Koulu, L., & Tuominen, R. (2013). The costs of psoriasis medications. Dermatology and Therapy, 3(2), 169-177. https://dx.doi.org/10.1007/s13555-013-0040-zPMid:24338674      PMCid:PMC3889304
22. Naldi, L., & Griffiths, C. E. M. (2005). Traditional therapies in the management of moderate to severe chronic plaque psoriasis: An assessment of the benefits and risks. The British Journal of Dermatology, 152(4), 597-615. https://dx.doi.org/10.1111/j.1365-2133.2005.06563.xPMid:15840088
23. Nijsten, T., Looman, C. W. N., & Stern, R. S. (2007). Clinical severity of psoriasis in last 20 years of PUVA study. Archives of Dermatology, 143(9), 1113-1121.https://dx.doi.org/10.1001/archderm.143.9.1113PMid:17875871
24. Norlin, J. M., Steen Carlsson, K., Persson, U., & Schmitt-Egenolf, M. (2015). Resource use in patients with psoriasis after the introduction of biologics in Sweden. Acta Dermato-Venereologica, 95(2), 156-161. https://dx.doi.org/10.2340/00015555-1895PMid:24819980
25. Radtke, M. A., & Augustin, M. (2008). Economic considerations in psoriasis management. Clinics in Dermatology, 26(5), 424-431. https://dx.doi.org/10.1016/j.clindermatol.2007.10.024PMid:18755360
26. Raho, G., Koleva, D. M., Garattini, L., & Naldi, L. (2012). The burden of moderate to severe psoriasis: An overview. Pharmacoeconomics, 30(11), 1005-1013. https://dx.doi.org/10.2165/11591580-000000000-00000PMid:22994598
27. Raychaudhuri, S. P., & Farber, E. M. (2001). The prevalence of psoriasis in the world. Journal of the European Academy of Dermatology and Venereology, 15(1), 16-17.https://dx.doi.org/10.1046/j.1468-3083.2001.00192.xPMid:11451313
28. Ruano, J., Isla-Tejera, B., Jiménez-Puya, R., Rodriguez-Martin, A., Cárdenas, M., Gómez, F., & Moreno-Giménez. J. C. (2013). Long-term cost-effectiveness analysis of etanercept and adalimumab for plaque psoriasis not associated with arthritis. Dermatology and Therapy, 3(2), 131-142. https://dx.doi.org/10.1007/s13555-013-0030-1PMid:24318413      PMCid:PMC3889303
29. Sampogna, F., Tabolli, S., Söderfeldt, B., Axtelius, B., Aparo, U., & Abeni, D. (2006). Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. The British Journal of Dermatology, 154(5), 844-9. https://dx.doi.org/10.1111/j.1365-2133.2005.07071.xPMid:16634884
30. Sandoval, L. F., Pierce, A. & Feldman, S. R. (2014). Systemic therapies for psoriasis: an evidence-based update. American Journal of Clinical Dermatology, 15(3), 165-80.https://dx.doi.org/10.1007/s40257-014-0064-xPMid:24496885
31. Schmitt, J. M., & Ford, D. E. (2006). Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology, 213(2), 102-110. https://dx.doi.org/10.1159/000093848PMid:16902286
32. Spandonaro, F., Ayala, F., Berardesca, E., Chimenti, S., Girolomoni, G., Martini, P., & Pinton, P. C. (2014). The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs, 28(3), 285-95. https://dx.doi.org/10.1007/s40259-014-0084-3PMid:24567261      PMCid:PMC4030097
33. Steinke, F., Wolfrum, P., & Hoffmann, C. (2013). Grid vs. storage in a 100% renewable Europe. Renewable Energy, 50, 826-832. https://dx.doi.org/10.1016/j.renene.2012.07.044
34. Stern, R. S., Nijsten, T., Feldman, S. R., Margolis, D. J., & Rolstad, T. (2004). Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. Journal of Investigative Dermatology Symposium Proceedings, 9(2), 136-139. https://dx.doi.org/10.1046/j.1087-0024.2003.09102.xPMid:15083780
35. Yu, A. P., Tang, J., Xie, J., Wu, E. Q., Gupta, S. R., Bao, Y., & M. Mulani, P. (2009). Economic burden of psoriasis compared to the general population and stratified by disease severity. Current Medical Research & Opinion, 25(10), 2429-2438. https://dx.doi.org/10.1185/03007990903185557PMid:19663687
36. Zhu, T. Y., Tam, L. S., Leung, Y. Y., Kwok, L. W., Wong, K. C., Yu, T., & Li, E. K. (2010). Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. The Journal of Rheumatology, 37(6), 1214-1220. https://dx.doi.org/10.3899/jrheum.090988PMid:20360186

Azizam, N. A., Ismail, A., Sulong, S., NOR, M. N., & Ahmed, Z. (2015). Economic burden of psoriasis: A Review of literature. International Journal of Business and Administrative Studies, 1(1), 18-22.